Galbán C, Montejo J C, Mesejo A, Marco P, Celaya S, Sánchez-Segura J M, Farré M, Bryg D J
Complejo Hospitalario Universitario, Santiago de Compostela, La Coruña, Spain.
Crit Care Med. 2000 Mar;28(3):643-8. doi: 10.1097/00003246-200003000-00007.
To determine whether early enteral feeding in a septic intensive care unit (ICU) population, using a formula supplemented with arginine, mRNA, and omega-3 fatty acids from fish oil (Impact), improves clinical outcomes, when compared with a common use, high protein enteral feed without these nutrients.
A prospective, randomized, multicentered trial.
ICUs of six hospitals in Spain.
One hundred eighty-one septic patients (122 males, 59 females) presenting for enteral nutrition in an ICU.
Septic ICU patients with Acute Physiology and Chronic Health Evaluation (APACHE) II scores of > or =10 received either an enteral feed enriched with arginine, mRNA, and omega-3 fatty acids from fish oil (Impact), or a common use, high protein control feed (Precitene Hiperproteico).
One hundred seventy-six (89 Impact patients, 87 control subjects) were eligible for intention-to-treat analysis. The mortality rate was reduced for the treatment group compared with the control group (17 of 89 vs. 28 of 87; p < .05). Bacteremias were reduced in the treatment group (7 of 89 vs. 19 of 87; p = .01) as well as the number of patients with more than one nosocomial infection (5 of 89 vs. 17 of 87; p = .01). The benefit in mortality rate for the treatment group was more pronounced for patients with APACHE II scores between 10 and 15 (1 of 26 vs. 8 of 29; p = .02).
Immune-enhancing enteral nutrition resulted in a significant reduction in the mortality rate and infection rate in septic patients admitted to the ICU. These reductions were greater for patients with less severe illness.
确定在脓毒症重症监护病房(ICU)患者中,与使用不含这些营养素的常用高蛋白肠内营养制剂相比,使用添加精氨酸、mRNA和鱼油中ω-3脂肪酸的配方制剂(Impact)进行早期肠内喂养是否能改善临床结局。
一项前瞻性、随机、多中心试验。
西班牙六家医院的ICU。
181例在ICU接受肠内营养的脓毒症患者(男性122例,女性59例)。
急性生理与慢性健康状况评分系统(APACHE)II评分≥10分的脓毒症ICU患者,要么接受富含精氨酸、mRNA和鱼油中ω-3脂肪酸的肠内营养制剂(Impact),要么接受常用的高蛋白对照制剂(Precitene Hiperproteico)。
176例(89例接受Impact治疗的患者,87例对照受试者)符合意向性分析标准。与对照组相比,治疗组的死亡率降低(89例中的17例 vs. 87例中的28例;p<0.05)。治疗组的菌血症减少(89例中的7例 vs. 87例中的19例;p = 0.01),且多重医院感染患者数量也减少(89例中的5例 vs. 87例中的17例;p = 0.01)。治疗组在死亡率方面的获益在APACHE II评分为10至15分的患者中更为显著(26例中的1例 vs. 29例中的8例;p = 0.02)。
免疫增强型肠内营养可显著降低入住ICU的脓毒症患者的死亡率和感染率。病情较轻的患者降低幅度更大。